

New Hampshire Medicaid Fee-for-Service Program

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Criteria

Approval Date: July 12, 2022

Pharmacology

Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid plaques and neurofibrillary/tau tangles are hallmark indicators of Alzheimer’s disease.

Medications

Brand Name	Generic Name	Dosage Strengths
Aduhelm™	aducanumab-avwa	170 mg/1.7 mL and 300 mg/3 mL solution in single dose vial for IV infusion

Criteria for Approval

Will follow Medicare coverage decision for dual eligible beneficiaries.

1. Patient is ≥ 18 years of age; **AND**
2. Patient has mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or has mild Alzheimer’s disease as evidenced by all of the following:
 - a. Clinical Dementia Rating (CDR) – Global Score of 0.5; **AND**
 - b. Objective evidence of cognitive impairment at screening; **AND**
 - c. Mini-Mental Status Exam (MMSE) score between 24 and 30 (inclusive); **AND**
 - d. Positron Emission Tomography (PET) scan is positive for amyloid beta plaque or FDA approved test to confirm diagnosis; **AND**
3. Other conditions mimicking, but of non-Alzheimer’s dementia etiology, have been ruled out (e.g. vascular dementia, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD], normal pressure hydrocephalus); **AND**
4. Patient has not had a stroke or transient ischemic attack (TIA) or unexplained loss of consciousness in the past 12 months; **AND**

Proprietary & Confidential

© 2022 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

5. Patient does not have any relevant brain hemorrhage, bleeding disorder, cerebrovascular abnormalities, or recent (within the prior year) cardiovascular condition (e.g., unstable angina, myocardial infarction, advanced congestive heart failure [CHF], or clinically significant conduction abnormalities); **AND**
6. Patient is not currently receiving anti-platelet agents, anticoagulants, or anti-thrombins (except for prophylactic aspirin at doses < 325 mg daily); **AND**
7. Drug must be prescribed by, or in consultation with, a specialist in neurology or gerontology; **AND**
8. Patient has received a baseline brain magnetic resonance imaging (MRI) prior to initiating treatment; **AND**
 - a. Within 1 year prior unless the patient has a more recent exacerbation, traumatic event [e.g., falls], or co-morbidity necessitating an evaluation within 1 month preceding initiation.
9. Patient will receive brain MRI throughout therapy (prior to the 7th and 12th dose); **AND**
10. Dosing and titration follow product labeling; **AND**
11. Patient does not have any of the following within 1 year of treatment initiation:
 - a. Pre-treatment localized superficial siderosis
 - b. ≥ 10 brain microhemorrhages
 - c. Brain hemorrhage > 1 cm; **AND**
12. Prescriber has assessed and documented baseline disease severity utilizing an objective measure/tool (e.g., MMSE, Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog-13], Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment version [ADCS-ADL-MCI], Clinical Dementia Rating-Sum of Boxes [CDR-SB]); **AND**
13. Prescriber has informed the patient of the known or potential risks and minimal established clinical benefit based on clinical trials to date with Aduhelm™ treatment.

Criteria for Renewal

1. Patient continues to meet the above criteria; **AND**
2. Patient has not had unacceptable toxicity from the drug (e.g., amyloid related imaging abnormalities [ARIA]-edema [ARIA-E], severe hypersensitivity reactions); **AND**
3. Patient has responded to therapy compared to pre-treatment baseline as evidenced by improvement, stability, or slowing in cognitive and/or functional impairment in ≥ 1 of the following (not all-inclusive) objective measures assessed and documented at baseline:
 - a. ADAS-Cog 13,
 - b. ADCS-ADL-MCI,
 - c. MMSE,
 - d. CDR-SB; **AND**

4. Patient has not progressed to moderate or severe AD; **AND**
5. Patient must continue maintenance therapy at the recommended dosage of 10 mg/kg every 4 weeks*; **AND**
6. Patient has received an MRI prior to the 7th and 12th doses for monitoring of ARIA-hemosiderin (ARIA-H) microhemorrhages; **AND**
 - a. Patient has < 10 new incident microhemorrhages or ≤ 2 focal areas of superficial siderosis (radiographic mild to moderate ARIA-H) observed; **OR**
 - b. Patient has ≥ 10 new incident microhemorrhages or > 2 focal areas of superficial siderosis (radiographic severe ARIA-H⁺) are observed **AND** patient meets the following criteria:
 - i. Treatment is continued with caution only after a clinical evaluation; **AND**
 - ii. Subsequent follow-up MRI demonstrates radiographic stabilization (e.g., no increase in size or number of ARIA-H).

Length of Authorization: 6 months

ARIA Classification and Radiographic Severity			
Severity	ARIA-E (based on FLAIR hyperintensity)	ARIA-H microhemorrhage (quantity of new incident microhemorrhages)	ARIA-H superficial siderosis (quantity of superficial siderosis focal areas)
Mild	Confined to sulcus and/or cortex/subcortical white matter in 1 location < 5 cm	≤ 4	1
Moderate	5 to 10 cm, or > 1 site of involvement, each measuring < 10 cm	5 to 9	2
Severe	> 10 cm, often with significant subcortical white matter and/or sulcal involvement; ≥ 1 separate site of involvement may be noted	≥ 10	> 2

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	06/02/2022
Commissioner Designee	Approval	07/12/2022